BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kabatas S, Civelek E, Boyalı O, Sezen GB, Ozdemir O, Bahar-Ozdemir Y, Kaplan N, Savrunlu EC, Karaöz E. Safety and efficiency of Wharton’s Jelly-derived mesenchymal stem cell administration in patients with traumatic brain injury: First results of a phase I study. World J Stem Cells 2024; 16(6): 641-655 [PMID: 38948099 DOI: 10.4252/wjsc.v16.i6.641]
URL: https://www.wjgnet.com/1948-0210/full/v16/i6/641.htm
Number Citing Articles
1
Muzamil Akhtar, Abdulqadir J Nashwan. Evaluating Wharton’s jelly-derived stem cell therapy in autism: Insights from a case studyWorld Journal of Methodology 2025; 15(2): 100074 doi: 10.5662/wjm.v15.i2.100074
2
P. R. Kamchatnov, O. Yu. Tsarapkina, N. G. Malyukova, A. V. Miretskaya, E. F. Danshina, L. A. Skipetrova, R. A. Cheremin. Treatment of post-traumatic cognitive disorders and asthenia: results of an observational studyNeurology, Neuropsychiatry, Psychosomatics 2024; 16(4): 14 doi: 10.14412/2074-2711-2024-4-14-20